Recent Quotes (30 days)

You have no recent quotes
chg | %

Synergy Pharmaceuticals Inc  

(Public, NASDAQ:SGYP)   Watch this stock  
Find more results for SGYP
1.89
-0.03 (-1.56%)
Real-time:   11:45AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.89 - 1.94
52 week 1.68 - 7.15
Open 1.94
Vol / Avg. 2.88M/8.25M
Mkt cap 466.19M
P/E     -
Div/yield     -
EPS -1.16
Shares 246.66M
Beta 1.28
Inst. own 62%
Nov 9, 2017
Q3 2017 Synergy Pharmaceuticals Inc Earnings Call - Webcast
Sep 26, 2017
Synergy Pharmaceuticals Inc at Ladenburg Thalmann Healthcare Conference
Sep 25, 2017
Synergy Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference
Sep 11, 2017
Synergy Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
Sep 7, 2017
Q2 2017 Synergy Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -975.86% -
Operating margin -952.48% -
EBITD margin - -
Return on average assets -156.39% -193.03%
Return on average equity -941.37% -
Employees 116 -
CDP Score - -

Address

420 Lexington Ave Rm 2012
NEW YORK, NY 10170-2099
United States - Map
+1-212-2970020 (Phone)
+1-212-2970019 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders. TRULANCE is designed to replicate the function of uroguanylin. Dolcanatide is being evaluated for inflammatory bowel disease (IBD). TRULANCE is approved in the United States under the trademark name TRULANCE, for the treatment of adults with chronic idiopathic constipation (CIC). In addition, it is developing TRULANCE for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Dolcanatide is designed to be an analog of uroguanylin with enhanced resistance to standard digestive breakdown by proteases in the intestine.

Officers and directors

Gary S. Jacob Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 70
Bio & Compensation  - Reuters
Gary G. Gemignani Chief Financial Officer, Executive Vice President
Age: 52
Bio & Compensation  - Reuters
Marino Garcia Executive Vice President, Chief Strategy Officer
Age: 50
Bio & Compensation  - Reuters
Patrick H. Griffin M.D. Executive Vice President, Chief Medical Officer
Age: 61
Bio & Compensation  - Reuters
Troy Hamilton Executive Vice President, Chief Commercial Officer
Age: 45
Bio & Compensation  - Reuters
Melvin K. Spigelman M.D. Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
Thomas H. Adams Jr. Ph.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
John P. Brancaccio CPA Independent Director
Age: 69
Bio & Compensation  - Reuters
Timothy S. Callahan Independent Director
Age: 46
Bio & Compensation  - Reuters
Richard J. Daly Independent Director
Age: 64
Bio & Compensation  - Reuters